FAQ on Quantum BioPharma Ltd.'s CDMO Agreement for Oral Lucid-MS in Phase 2 MS Trial

What is Quantum BioPharma Ltd. announcing?

Quantum BioPharma Ltd. announced that its subsidiary, Huge Biopharma Australia Pty Ltd., has signed an agreement with a leading contract development and manufacturing organization (CDMO) to produce an oral formulation of Lucid-MS for an upcoming Phase 2 clinical trial in multiple sclerosis (MS).

What is Lucid-MS?

Lucid-MS is a patented, first-in-class, non-immunomodulatory neuroprotective compound that has shown the ability to prevent demyelination, a key feature of MS and other neurodegenerative diseases, in preclinical studies.

Why is this agreement significant?

This agreement is a key step towards filing an Investigational New Drug (IND) application with the FDA for Lucid-21-302 in MS, potentially advancing the treatment towards clinical use.

What are the goals of the Phase 2 clinical trial?

The Phase 2 clinical trial will evaluate Lucid-MS as a potential treatment to help restore mobility in people with MS, based on preclinical studies where the therapy enabled animals to regain their ability to walk.

Who is involved in this agreement?

Quantum BioPharma Ltd., through its subsidiary Huge Biopharma Australia Pty Ltd., and a leading CDMO are involved in this agreement to produce the oral formulation of Lucid-MS.

Where can I find more information about Quantum BioPharma Ltd.?

More information about Quantum BioPharma Ltd. and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.

What other projects does Quantum BioPharma Ltd. have?

Quantum BioPharma Ltd. is focused on building a portfolio of innovative assets for the treatment of neurodegenerative and metabolic disorders, including its lead compound Lucid-MS, and maintains strategic investments through its subsidiary, FSD Strategic Investments Inc.

How does Lucid-MS compare to other MS treatments?

Lucid-MS is a first-in-class, non-immunomodulatory neuroprotective compound that has demonstrated the ability to prevent demyelination, distinguishing it from other treatments that primarily modulate the immune system.

What is the significance of the preclinical studies mentioned?

The preclinical studies are significant because they showed that Lucid-MS could enable animals to regain their ability to walk, suggesting potential for restoring mobility in people with MS.

How can investors stay updated on Quantum BioPharma Ltd.’s progress?

Investors can stay updated by visiting the company’s newsroom at https://ibn.fm/QNTM for the latest news and updates relating to QNTM.